• TPPU: Soluble Epoxide Hydrolase Inhibitor Workflows

  2026-08-14

  TPPU enables nanomolar interrogation of sEH-dependent lipid signaling in inflammatory pain, osteoclast, and liver–bone studies. This guide connects assay design, sample handling, pharmacodynamic readouts, and troubleshooting to help researchers distinguish target engagement from nonspecific effects.

• Lipo3K Transfection Reagent: Practical Workflow Guide

  2026-08-13

  Build reliable DNA, mRNA, siRNA, and multiplexed assays with a low-toxicity lipid transfection reagent designed for adherent, suspension, and difficult-to-transfect cells. This guide connects Lipo3K workflows with pH-responsive antisense research, emphasizing practical controls, optimization, and interpretation limits.

• Measuring Drug Response in Cancer In Vitro

  2026-08-13

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. By separating growth inhibition from cell killing and considering their timing, the work provides a more informative framework for interpreting in vitro cancer pharmacology.

• Phenothiazines, ROS, and Macrophage Antibacterial Defense

  2026-08-12

  Qiu et al. report that phenothiazines strengthen macrophage control of intracellular bacteria by increasing reactive oxygen species, lysosomal activity, and autophagy. Perphenazine also reduced organ injury and inflammation in a Salmonella Typhimurium infection model, supporting phenothiazines as lead compounds for host-directed antibacterial research.

• pH-Sensitive Nanoparticles Reverse BCSC Drug Resistance

  2026-08-12

  The reference study developed SchB/AP nanoparticles to combine ATRA-based tumor-cell targeting with schisandrin B-mediated reversal of multidrug resistance in breast cancer stem cells. Its in vitro findings link pH-responsive release, lysosomal escape, reduced P-glycoprotein activity, and altered drug-efflux energy supply to improved cytotoxicity against resistant cells.

• Rotigotine and Bladder Function in Parkinson’s Rats

  2026-08-11

  The reference study shows that rotigotine produces route-dependent changes in bladder activity in a 6-hydroxydopamine rat model of Parkinson’s disease. Its central contribution is to connect dopaminergic pharmacology with cystometric measures of overactive bladder, while also highlighting why acute injection data should not be directly equated with transdermal treatment.

• Otilonium Bromide: Workflow and Assay Guide

  2026-08-10

  Build cleaner muscarinic-response assays with Otilonium Bromide, an antimuscarinic agent suited to cholinergic signaling, smooth muscle, and receptor-modulation workflows. Practical dilution guidance, control design, and troubleshooting help distinguish true pharmacology from solvent, viability, and tissue-preparation artifacts.

• Morin: Mechanisms, Evidence, and Research Use

  2026-08-09

  Morin is the natural flavonoid 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, used to study oxidative stress, inflammation, mitochondrial metabolism, and metal-ion sensing. Its research value is broad, but assay-specific validation is required because product specifications do not establish clinical efficacy.

• Rotigotine: Designing Translational PD Assays

  2026-08-08

  Rotigotine is a dopamine D2/D3 receptor agonist with a distinctive opportunity for linking receptor pharmacology, neuroprotection, and brain-targeted delivery. This article presents an endpoint-driven framework for translating cell and animal findings into more interpretable Parkinson’s disease research assays.

• Serine/Glycine Restriction, PD-L1 Lactylation, and CRC

  2026-08-07

  This Cell Metabolism study shows that a serine/glycine-free diet can restrict colorectal cancer growth while increasing cytotoxic T-cell accumulation, but may also promote immune evasion through PD-L1 lactylation. Its preclinical findings and single-arm phase I evaluation support combining metabolic dietary interventions with checkpoint blockade, while emphasizing the need for mechanistic and clinical validation.

• Dissecting Proliferation and Death in Cancer Drug Response A

  2026-08-07

  Schwartz's dissertation introduces a rigorous framework to distinguish between cancer cell proliferation arrest and cell death in in vitro drug response assays. By clarifying how these two effects are measured and interpreted, the work enhances the reliability of preclinical evaluations and may guide more nuanced use of mTOR inhibitors such as Everolimus in translational research.

• OsCPK4–OsCNGC7 Phosphorylation Loop Enhances Rice Salt Toler

  2026-08-06

  This study uncovers a phosphorylation-centered feedback loop involving OsCPK4 and OsCNGC7 that fine-tunes Ca2+ influx, conferring salt tolerance in rice. The mechanistic insights into protein phosphorylation dynamics highlight new avenues for crop stress research and practical detection strategies.

• PDHA1 Succinylation Drives Immune Evasion in Cholangiocarcin

  2026-08-06

  This study elucidates how succinylation of PDHA1 at lysine 83 in cholangiocarcinoma disrupts tricarboxylic acid cycle flux, leading to alpha-ketoglutarate accumulation and suppression of macrophage antigen presentation. These findings reveal a metabolic-immune axis underlying tumor immune escape and highlight PDHA1 succinylation as a promising therapeutic target to enhance chemotherapy efficacy.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Workflow Guide

  2026-08-05

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1223) provides researchers with a reliable, affinity-purified secondary antibody for sensitive detection of rabbit IgG in immunoassays such as Western blot, ELISA, and immunohistochemistry. It is not intended for diagnostic or therapeutic use, and care must be taken to follow storage and protocol recommendations to maximize specificity and minimize background.

• Enzymatic Synthesis of Fatty Amines from Trilaurin: Advances

  2026-08-05

  This article examines the direct enzymatic synthesis of primary fatty amines from renewable triglycerides, with a focus on trilaurin (glycerol tridodecanoate) as a model substrate. The reference study presents a one-pot biocatalytic strategy that achieves high yield and selectivity under mild conditions, offering a sustainable alternative to conventional chemical routes.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page